Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

White House Opioid Commission Interim Report Recommendations May Make the Nation's Drug Problem Worse
  • USA - English


News provided by

Center for Network Therapy

Aug 03, 2017, 16:40 ET

Share this article

Share toX

Share this article

Share toX

(PRWEB) August 03, 2017 -- The White House Opioid Commission’s Interim Report shines a bright light on America’s opioid epidemic; 142 people dying from drug overdose every single day. The Center for Network Therapy (CNT) estimated that the cost of the drug epidemic exceeds $1 trillion every year. (Read CNT's recent press release on this topic here.) Dr. Indra Cidambi, leading Addiction Medicine expert and Medical Director at CNT, New Jersey’s first licensed outpatient detoxification facility, fears that many of the recommendations may not help much and some may actually make the drug problem worse.

Dr. Cidambi analyzed the interim report’s recommendations and explained why:

• Increasing inpatient treatment capacity constitutes an expansion of a failed model: The report recommends Medicaid limitations for inpatient treatment be removed. However, the drug epidemic is proof that the traditional inpatient treatment modalities have largely failed even people with private health insurance not subject to such limitations. “So more of the same may help on the margin at best, but supporting nascent addiction treatment modalities such as the Ambulatory (Outpatient) Detoxification is the key to delivering far better outcomes in an economic manner,” says Dr. Cidambi. The outpatient model incorporates an individual’s living environment into treatment, which helps deliver better results.

• Increasing opioid prescriber education may not stop the creation of new addicts: “65% of opioid pain prescriptions are written by Family Doctors and Nurse Practitioners, not pain management specialists,” notes Dr. Cidambi. “While educating these prescribers is important, a better alternative would be limiting the ability to prescribe opiate pain medications only to physicians with specialized training in pain management (such as surgeons, oncologists and orthopedic and pain management specialists). We need to stop creating addicts as a more comprehensive opioid curriculum is worked into the medical education system.”

• Medication Assisted Treatment (MAT) is not a panacea: MAT primarily consists of prescribing buprenorphine or methadone and, to some highly-motivated individuals, naltrexone in order to address cravings and withdrawal symptoms for individuals afflicted with the disease of addiction. “Recklessly expanding the number of prescribers of these medications will only intensify the problem; these medications are only effective when accompanied by therapy to help encourage lifestyle changes, as well as monitoring to ensure these patients are not using other drugs concurrently,” says Dr. Cidambi. “We are sure to find people with addiction issues leverage the easy availability of such prescriptions to detox themselves when they run out of money to buy drugs or use it as currency on the street to buy other drugs.” Mixing these medications with other drugs or prescription medications could be dangerous.

• Making Naloxone (Narcan) available to people addicted to opiates may encourage riskier behavior: Naloxone is an opiate overdose reversal drug used by first responders and other emergency medical care professionals. “Requiring opioid prescriptions to be complemented by Naloxone prescriptions appears logical on the surface but it is a double-edged sword. I fear it may encourage people abusing opioid pain pills to chase a ‘higher high,’ as they have the antidote to overdose on hand,” noted Dr. Cidambi. While all emergency medical professionals and first responders should be equipped with Naloxone, handing it out to opioid pain medication abusers could actually increase the chances of overdose. Also, overdoses are not intentional and the ability to recognize and self-administer Naloxone at the point of overdose is questionable.

• Development and deployment of fentanyl sensors will likely be futile: The opioid commission’s assumption is that Fentanyl is smuggled into the country as a finished product, but the reality is a little more complex. “On shoring of Fentanyl is happening fast and drug dealers are importing base chemicals (that can be combined in home-size labs to make Fentanyl) and pill making machines (disassembled and shipped in separate packages) from China and making the fentanyl pills themselves,” says Dr. Cidambi. Therefore, screening for fentanyl is unlikely to yield optimal results. A better option would be to leverage our terror tracking apparatus to track orders of raw materials over the internet and the dark web.

• Exploding demand for street heroin will not show in national prescription monitoring programs: Currently, most prescription monitoring databases are localized to one state and the opioid commission recommends a national database. It would definitely help identify ‘doctor shopping’ across state lines for prescription opiate pain medications. “However, this may be similar to locking the stable door after the horse has bolted,” says Dr. Cidambi. “Drug dealers are awesome competitors and street prices of heroin and heroin laced with fentanyl have fallen so much that opioid overdose deaths in 2015 continued to climb despite a significant decline in opioid pain prescriptions. Individuals addicted to opiates simply switched to cheaper and more potent street drugs.” If the crackdown on legal prescriptions intensifies it will push more people to street drugs.

• Enforcing the Mental Health Parity and Addiction Equity Act (MHPAEA) should be accompanied by support for newer treatment modalities: “Every day I see patients whose health insurance provider either does not provide sufficient coverage for substance use disorders or they face a high deductible,” says Dr. Cidambi. Either way, many individuals suffering from substance use disorders are unable to access treatment. “There is also resistance in the treatment community to innovative, higher efficacy and lower cost treatment models such as Ambulatory Detoxification, which I introduced in the state of New Jersey.” The cost of traditional inpatient treatment is high and burdensome regulations play a big part in driving costs higher. In order to lighten the costs of treatment on society as a whole, lower cost modalities of care such as Ambulatory Detoxification should be strongly supported while enforcing MHPAEA.

• Easing HIPAA regulations should help: While HIPAA was designed to protect the patient’s privacy, with substance use disorders it cuts both ways. “In many instances, I find sharing information with other care providers greatly enhances the patient’s recovery, as it avoids patients receiving multiple prescriptions. But HIPAA is restrictive when the patient has not signed a release to share information. HIPAA actually serves to increase the relapse rate, so this recommendation could truly help, and may save lives in case of overdose.”

• While decriminalizing drug possession is important, it is not one of the opioid commission's recommendations: In 2015, there were roughly 1.5 million arrests for drug law violations and four out of five were for possession. Decriminalization of drug possession related violations may offer the biggest bang for the buck because, according to the U.S. Department of Justice, more than 50% of the costs tied to illicit drug use related to criminal justice and incarceration. “It is time we utilize the ‘token economy’ modality of treatment that universally offers individuals a clean record upon successful completion of addiction treatment. This would cut criminal justice costs dramatically and also enable those in recovery to more easily re-integrate into the job market,” said Cidambi. This will also save money that can be utilized to fund other initiatives.

About Center for Network Therapy
Center for Network Therapy (CNT) was the first facility in New Jersey to be licensed to provide Ambulatory (Outpatient) Detoxification Services for all substances of abuse – alcohol, anesthetics, benzodiazepines, opiates and other substances of abuse. Led by a Board-Certified Addiction Psychiatrist, Indra Cidambi, M.D., experienced physicians and nurses closely monitor each patient’s progress. With CNT’s superior client care and high quality treatment, Dr. Cidambi and her clinical team have successfully detoxed over 1,000 patients in four years. The Center for Network Therapy also offers step down to Partial Care (PHP and Intensive Outpatient (IOP) levels of care.

Marisa Amador, Center for Network Therapy, +1 212.805.3029, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.